What is HC Wainwright’s Estimate for BDTX FY2025 Earnings?

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – HC Wainwright lifted their FY2025 EPS estimates for Black Diamond Therapeutics in a note issued to investors on Wednesday, November 12th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of $0.46 for the year, up from their prior forecast of $0.33. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q4 2025 earnings at ($0.19) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($0.83) EPS.

Several other research analysts have also recently commented on BDTX. Wall Street Zen cut Black Diamond Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Stifel Nicolaus assumed coverage on Black Diamond Therapeutics in a report on Wednesday, October 15th. They set a “buy” rating and a $8.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Black Diamond Therapeutics in a research report on Wednesday, October 8th. Zacks Research cut Black Diamond Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 10th. Finally, Guggenheim started coverage on shares of Black Diamond Therapeutics in a research report on Wednesday, September 3rd. They set a “buy” rating and a $8.00 price target for the company. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.60.

Black Diamond Therapeutics Price Performance

NASDAQ:BDTX opened at $4.01 on Friday. The firm has a 50-day moving average of $3.77 and a two-hundred day moving average of $2.92. The stock has a market cap of $228.45 million, a P/E ratio of 11.14 and a beta of 3.12. Black Diamond Therapeutics has a 1-year low of $1.20 and a 1-year high of $4.94.

Black Diamond Therapeutics (NASDAQ:BDTX) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07.

Institutional Trading of Black Diamond Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC acquired a new stake in Black Diamond Therapeutics during the second quarter worth about $28,000. AWM Investment Company Inc. acquired a new position in Black Diamond Therapeutics in the first quarter valued at approximately $775,000. Brown Wealth Management LLC bought a new position in shares of Black Diamond Therapeutics during the first quarter valued at approximately $155,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Black Diamond Therapeutics during the 2nd quarter worth approximately $36,000. Finally, DLK Investment Management LLC raised its position in shares of Black Diamond Therapeutics by 26.3% during the 2nd quarter. DLK Investment Management LLC now owns 20,200 shares of the company’s stock worth $50,000 after purchasing an additional 4,200 shares during the period. Institutional investors own 95.47% of the company’s stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.